TCGA-OL-A66N-01A-12R-A31O-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 26
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.370
- COAGULATION+0.350
- PANCREAS_BETA_CELLS+0.310
- KRAS_SIGNALING_DN+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- ANGIOGENESIS+0.180
- OXIDATIVE_PHOSPHORYLATION+0.180
- APICAL_SURFACE+0.160
- BILE_ACID_METABOLISM+0.160
- KRAS_SIGNALING_UP+0.160
Top 10 suppressed
- G2M_CHECKPOINT-0.640
- E2F_TARGETS-0.590
- MITOTIC_SPINDLE-0.510
- PROTEIN_SECRETION-0.490
- INTERFERON_ALPHA_RESPONSE-0.460
- TGF_BETA_SIGNALING-0.420
- MTORC1_SIGNALING-0.370
- MYC_TARGETS_V1-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
- PI3K_AKT_MTOR_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.885 |
| 2 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.875 |
| 3 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.852 |
| 4 | MNG756 | — | — | 0.849 |
| 5 | TCGA-WT-AB44-01A-11R-A41B-07 | — | B | 0.837 |
| 6 | TCGA-LL-A5YL-01A-12R-A29R-07 | — | B | 0.836 |
| 7 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.833 |
| 8 | TCGA-S5-A6DX-01A-11R-A31N-07 | — | — | 0.832 |
| 9 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.830 |
| 10 | MDT-AP-1200 | Med | Medulloblastoma | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |